Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | F12 | P00748 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 1/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GOT1 | P17174 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL5804370 | 0.98 | PLAU (0.53) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL6175758 | 0.83 | EGFR (0.56) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL34467229 | 0.83 | EGFR (0.56) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL4479184 | 0.79 | CYP2A6 (0.55) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL27931662 | 0.79 | FDPS (0.51) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL24170548 | 0.79 | FDPS (0.51) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL1133566 | 0.79 | FDPS (0.56) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL6435471 | 0.77 | FDPS (0.50) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL10717431 | 0.76 | FDPS (0.49) | PLAUF12NCF1NOS3NOS1 | |
| SCHEMBL1921849 | 0.76 | ABCG2 (0.53) | PLAUF12NCF1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160848-A1 | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes | ADELAIDE, THE UNIVERSITY OF (AU) | 2006-07-20 | — | — | US | claimed |
| WO-2006002473-A1 | METHOD OF CONTROLLING DAMAGE MEDIATED BY ALPHA, BETA-UNSATURATED ALDEHYDES | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2006-01-12 | — | — | WO | claimed |
| US-20250136987-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | disclosed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | disclosed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-20230174980-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-110483481-B | Indole-substituted dihydroisoquinoline compound and synthesis method thereof | 湖南科技大学 | 2022-09-16 | — | — | CN | disclosed |
| WO-2006023750-A2 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006002473-A1 | METHOD OF CONTROLLING DAMAGE MEDIATED BY ALPHA, BETA-UNSATURATED ALDEHYDES | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2006-01-12 | — | — | WO | disclosed |
| WO-2002081474-A1 | TRIAZOLOPHTHALAZINE / QUINOLINE / ISOQUINOLINE DERIVATIVES WHICH ARE LIGANDS FOR GABA-A RECEPTORS CONTAINING THE ALPHA 5 SUBTYPE | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| EP-0224842-B1 | PYRAZOLESULFONAMIDE DERIVATIVE, PROCESS FOR ITS PRODUCTION AND HERBICIDE CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-4844728-A | Pyrazolesulfonamide derivative, and herbicide containing it | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4837308-A | Process for the preparation of azo compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| EP-0201892-B1 | METHOD OF MAKING AZO COMPOUNDS | BAYER AG (DE) | 1989-03-08 | — | — | EP | disclosed |
| EP-0201892-A1 | Method of making azo compounds | BAYER AG (DE) | 1986-11-20 | — | — | EP | disclosed |
| US-3992539-A | S-triazolo-[3,4-a]isoquinolines in treating inflammatory disorders | MALLINCKRODT, INC. (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174980-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | PLAU 3749/4885F12 2811/4885NCF1 2645/4885 |
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | PLAU 2442/4885F12 3880/4885NCF1 2397/4885 |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | PLAU 4527/4885F12 2878/4885NCF1 2448/4885 |
| US-20060160848-A1 | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes | ALDH2, ALDH1A1, HACL2 | PLAU 1708/4885F12 1811/4885NCF1 724/4885 |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | PLAU 4527/4885F12 2878/4885NCF1 2448/4885 |
| US-20250136987-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | PLAU 3749/4885F12 2811/4885NCF1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.